SIEGFRIED HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 951 CHF | +1.39% |
|
+3.03% | +10.65% |
| Sales 2024 * | 1.3B 1.44B | Sales 2025 * | 1.42B 1.57B | Capitalization | 4.02B 4.45B |
|---|---|---|---|---|---|
| Net income 2024 * | 148M 164M | Net income 2025 * | 173M 191M | EV / Sales 2024 * | 3.36 x |
| Net Debt 2024 * | 357M 395M | Net Debt 2025 * | 314M 347M | EV / Sales 2025 * | 3.05 x |
| P/E ratio 2024 * |
27.1
x | P/E ratio 2025 * |
23.2
x | Employees | 3,945 |
| Yield 2024 * |
0.4% | Yield 2025 * |
0.42% | Free-Float | 87.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Siegfried Holding AG
More recommendations
More press releases
| 1 day | +1.12% | ||
| 1 week | +2.71% | ||
| Current month | +1.61% | ||
| 1 month | +6.64% | ||
| 3 months | +7.12% | ||
| 6 months | +13.46% | ||
| Current year | +10.30% |
1 week
920.00
948.00
1 month
871.00948.00
Current year
827.00950.00
1 year
655.00950.00
3 years
566.00950.00
5 years
313.50950.00
10 years
136.20950.00
| Managers | Title | Age | Since |
|---|---|---|---|
Reto Suter
CEO | Chief Executive Officer | 53 | 17-04-30 |
Jürgen Roos
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-03-31 |
Christa Brügger
PRN | Corporate Officer/Principal | - | 14-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Schmid
BRD | Director/Board Member | 55 | 15-12-31 |
Wolfram Carius
BRD | Director/Board Member | 63 | 13-12-31 |
Andreas Casutt
CHM | Chairman | 61 | 09-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 775 M€ | -.--% | - | |
| 0.02% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 951 | +1.39% | 2 577 |
| 24-07-02 | 938 | -0.64% | 3,124 |
| 24-07-01 | 944 | +1.18% | 7,552 |
| 24-06-28 | 933 | +0.65% | 4,606 |
| 24-06-27 | 927 | +0.43% | 5,183 |
Delayed Quote Swiss Exchange, July 03, 2024 at 03:22 am EDT
More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
938
CHF
Average target price
1,016
CHF
Spread / Average Target
+8.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.30% | 4.45B | |
| +55.55% | 816B | |
| +41.41% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +13.81% | 238B | |
| +1.02% | 222B | |
| +13.40% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- SFZN Stock
